Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review
Cancer Chemotherapy and Pharmacology · 03.08.2026 · 96 (1)
DOI: 10.1007/s00280-026-04932-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 03.08.2026. Verfasst von Karolijn W M Groot Beumer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. k.groot@nki.nl. Hauptthemen laut MEDLINE: Achondroplasia, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction Currently, no established guidelines exist for dosing chemotherapy or immunotherapy in patients with achondroplasia. Case A 69-year old female with congenital achondroplasia was diagnosed with stage IV non-small cell lung carcinoma type adenocarcinoma, with high Tumor Mutational Burden and 20% programmed death-ligand 1 expression. The patient received carboplatin dose based on renal function utilizing measured creatinine clearance, pemetrexed based on body surface area and pembrolizumab at a fixed dose of 100mg for body weight
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. k.groot@nki.nl.
- Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Pharmacy, Research Institute for Medical Innovation, Radboudumc, Nijmegen, The Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
- Princess Maxima Centre for Paediatric Oncology, Utrecht, The Netherlands.
Zitieren
APA
Groot Beumer, K. W. M., Durlinger, E. M. J., Zielhuis, S. W. J., Ter Heine, R., Huitema, A. D. R., & Hendrikx, J. J. M. A. (2026). Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04932-7
Vancouver
Groot Beumer KWM, Durlinger EMJ, Zielhuis SWJ, Ter Heine R, Huitema ADR, Hendrikx JJMA. Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04932-7
BibTeX
@article{GrootBeumer2026,
author = {Groot Beumer, Karolijn W M and Durlinger, E M J and Zielhuis, S W J and Ter Heine, R and Huitema, A D R and Hendrikx, J J M A},
title = {Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04932-7}
}
EUVIMED